Advances in Pharmacology and Therapeutics II: Toxicology & experimental models
Title | Advances in Pharmacology and Therapeutics II: Toxicology & experimental models PDF eBook |
Author | |
Publisher | |
Pages | |
Release | 1982 |
Genre | Pharmacology |
ISBN |
Toxicology and Experimental Models
Title | Toxicology and Experimental Models PDF eBook |
Author | Hiroshi Yoshida |
Publisher | |
Pages | 376 |
Release | 1982 |
Genre | Animal experimentation |
ISBN | 9780080280257 |
Advances in Pharmacology and Therapeutics II, Volume 5: Toxicology and Experimental Models is the fifth of a six-volume compilation of the scientific papers of invited speakers of the Eighth International Congress of Pharmacology. Organized into six parts, this book begins by elucidating the rational interpretation of species and strain differences in toxicity for the prediction of risk to man. Subsequent parts discuss the chemical interactions resulting in liver and kidney injury; the role of heme synthesis and degradation in predicting drug toxicity; and delayed toxic effects of pre- and per.
Toxicology & experimental models
Title | Toxicology & experimental models PDF eBook |
Author | |
Publisher | |
Pages | |
Release | 1982 |
Genre | Pharmacology |
ISBN |
Toxicology and Experimental Models
Title | Toxicology and Experimental Models PDF eBook |
Author | H. Yoshida |
Publisher | Elsevier |
Pages | 366 |
Release | 2013-10-22 |
Genre | Medical |
ISBN | 1483148483 |
Advances in Pharmacology and Therapeutics II, Volume 5: Toxicology and Experimental Models is the fifth of a six-volume compilation of the scientific papers of invited speakers of the Eighth International Congress of Pharmacology. Organized into six parts, this book begins by elucidating the rational interpretation of species and strain differences in toxicity for the prediction of risk to man. Subsequent parts discuss the chemical interactions resulting in liver and kidney injury; the role of heme synthesis and degradation in predicting drug toxicity; and delayed toxic effects of pre- and perinatal drug exposure. Other chapters describe models of experimental peptic ulcers and therapeutic agents and models and quality control of laboratory animals.
Animal Experimentation: Working Towards a Paradigm Change
Title | Animal Experimentation: Working Towards a Paradigm Change PDF eBook |
Author | Kathrin Herrmann |
Publisher | BRILL |
Pages | 749 |
Release | 2019-04-30 |
Genre | Philosophy |
ISBN | 9004391193 |
Animal experimentation has been one of the most controversial areas of animal use, mainly due to the intentional harms inflicted upon animals for the sake of hoped-for benefits in humans. Despite this rationale for continued animal experimentation, shortcomings of this practice have become increasingly more apparent and well-documented. However, these limitations are not yet widely known or appreciated, and there is a danger that they may simply be ignored. The 51 experts who have contributed to Animal Experimentation: Working Towards a Paradigm Change critically review current animal use in science, present new and innovative non-animal approaches to address urgent scientific questions, and offer a roadmap towards an animal-free world of science.
Current Catalog
Title | Current Catalog PDF eBook |
Author | National Library of Medicine (U.S.) |
Publisher | |
Pages | 824 |
Release | 1993 |
Genre | Medicine |
ISBN |
First multi-year cumulation covers six years: 1965-70.
Improving and Accelerating Therapeutic Development for Nervous System Disorders
Title | Improving and Accelerating Therapeutic Development for Nervous System Disorders PDF eBook |
Author | Institute of Medicine |
Publisher | National Academies Press |
Pages | 107 |
Release | 2014-02-06 |
Genre | Medical |
ISBN | 0309292492 |
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.